E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
pain due to cancer |
dolore da cancro |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main aim of the study is to show non inferiority of sublingual fentanyl (SLF) with respect to subcutaneous morphine (SCMO) in the treatment of severe cancer pain episodes in the first 30 minutes after drug assumption, in cancer patients regularly treated with opioids.
Pain intensity in the first 30 minutes after drug administration, calculated as average value of pain “right now” scores at 10, 20 and 30 minutes after drug administration is the main outcome measure.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary efficacy endpoints are to compare:
a) analgesic efficacy at 60 minutes
b) proportion of patients needing a second dose of opioid
c) proportion of patients that express a preference for one administration route
d) safety and tolerability (adverse drug reactions (ADR), adverse events (AEs) and serious adverse events (SAE) occurring during the study).
e) effectiveness, safety and tolerability of SLF and SCMO in patients regularly on low dosages of opioids.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- active oncological disease causing pain
- stable opioid therapy (> 3 days)
- adequate pain control in the previous 24 hours (average pain in the previous 24 hours of ≤ 4/10)
- episode of breakthrough pain occurring at the time of the visit (current pain ≥ 6/10)
- previous 24 hours daily dosage of opioid, calculated as equianalgesic dose of oral morphine, between 20 and 120 mg/day
- written informed consent to study participation
- age ≥ 18 years
|
|
E.4 | Principal exclusion criteria |
cognitive deficits compromising the ability to assess pain or pain relief
- previous therapy with sublingual fentanyl
-pregnancy or breastfeeding
- severe hepatic and/or renal impairment
- participation in other clinical trial that might interfere with the study results
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
to show non inferiority of sublingual fentanyl (SLF) with respect to subcutaneous morphine (SCMO) in the treatment of severe cancer pain episodes in the first 30 minutes after drug assumption, in cancer patients regularly treated with opioids. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
at 0, 10, 20, 30, 60 minutes after the beginning of the study |
|
E.5.2 | Secondary end point(s) |
effectiveness, safety and tolerability of SLF and SCMO |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
after 30 and 60 minutes after the beginning of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
after 15 months from the first patients enclosed |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |